Upadacitinib for immune disorders from JAK/STAT mutations
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests a pill called upadacitinib (a JAK inhibitor) for people with certain gene changes that cause an overactive immune system. The goal is to see if the drug can help control immune-related symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Weigh at least 30 kg (about 66 pounds)
- Have a confirmed gene change (mutation) in the JAK or STAT genes that affects the immune system
- Have symptoms of immune system problems that meet the study's definition
- Be expected to live at least 12 more months
- Be willing to allow storage of blood or tissue samples for future research
- If you can get pregnant, agree to use reliable birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
This study tests whether upadacitinib, a pill that calms the immune system, can help people hospitalized with a severe flare of ulcerative colitis. It aims to see if the drug can reduce symptoms and help you leave the hospital sooner.
This study tests if the medication upadacitinib can help people whose eyelid rash has not improved with prescription creams. It's for adults who have had eyelid dermatitis for at least two months and have tried at least one prescribed cream that didn't work.
This trial tests a medicine called upadacitinib (an anti-JAK pill) for people with giant cell arteritis that affects the large arteries, especially the aorta. It is for those whose disease is active despite trying another treatment called tocilizumab, and aims to reduce inflammation and prevent damage.
This study tests a pill called upadacitinib (a JAK inhibitor) in people with eosinophilic esophagitis (EoE) that hasn't improved with swallowed steroids. It aims to see if the drug can reduce inflammation and symptoms in the esophagus when added to your current steroid treatment.
This trial tests the combination of upadacitinib (an immune-modulating drug) and high-dose dexamethasone (a steroid) as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). The goal is to see if this combination can raise your platelet count and reduce bleeding better than usual care.
Hear when a new JAK1 GOF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.